相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
Jedd D. Wolchok et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Experiences of resuming life after immunotherapy and associated survivorship care needs: a qualitative study among patients with metastatic melanoma
Nadia C. W. Kamminga et al.
BRITISH JOURNAL OF DERMATOLOGY (2022)
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
Jason J. Luke et al.
LANCET (2022)
Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067.
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
J. Haanen et al.
ANNALS OF ONCOLOGY (2022)
Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls
A. H. Boekhout et al.
ACTA ONCOLOGICA (2021)
Novel adjuvant options for cutaneous melanoma
F. Dimitriou et al.
ANNALS OF ONCOLOGY (2021)
Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma
J. Randall Patrinely et al.
JAMA ONCOLOGY (2021)
Frequency, Treatment and Outcome of Immune-Related Toxicities in Patients with Immune-Checkpoint Inhibitors for Advanced Melanoma: Results from an Institutional Database Analysis
Florentia Dimitriou et al.
CANCERS (2021)
An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors
Aine O'Reilly et al.
SUPPORTIVE CARE IN CANCER (2020)
Health-related quality of life, emotional burden, and neurocognitive function in the first generation of metastatic melanoma survivors treated with pembrolizumab: a longitudinal pilot study
A. Rogiers et al.
SUPPORTIVE CARE IN CANCER (2020)
Patient-reported outcomes in melanoma survivors at 1, 3 and 5 years post-diagnosis: a population-based cross-sectional study
Karolina Lisy et al.
QUALITY OF LIFE RESEARCH (2020)
Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors
Maha Mamoor et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee
U. Keilholz et al.
ANNALS OF ONCOLOGY (2020)
Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors
Anne Rogiers et al.
JOURNAL OF ONCOLOGY (2019)
The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors
Julia Lai-Kwon et al.
JOURNAL OF CANCER SURVIVORSHIP (2019)
Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors
Alvaro Moreira et al.
EUROPEAN JOURNAL OF CANCER (2019)
Fatigue in survivors of malignant melanoma and its determinants: a register-based cohort study
Ana Nanette Tibubos et al.
SUPPORTIVE CARE IN CANCER (2019)
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
ClinicalTrials.gov for Facilitating Rapid Understanding of Potential Harms of New Drugs: The Case of Checkpoint Inhibitors
Annie Yang et al.
JOURNAL OF ONCOLOGY PRACTICE (2018)
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis
Daniel Y. Wang et al.
JAMA ONCOLOGY (2018)
Targeted agents and immunotherapies: optimizing outcomes in melanoma
Jason J. Luke et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
J. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A systematic review and network meta-analysis of immunotherapy and targeted therapy for advanced melanoma
Joao Paulo da Silveira Nogueira Lima et al.
CANCER MEDICINE (2017)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Matias E. Valsecchi
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Age- and sex-standardised prevalence rates of fatigue in a large hospital-based sample of cancer patients
S. Singer et al.
BRITISH JOURNAL OF CANCER (2011)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)